idh305
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2015 (NCT02381886)
Timeline
Indications
Mechanism of action
IDH1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc([C@H](C)Nc2nccc(N3C(=O)OC[C@@H]3[C@@H](C)F)n2)ncc1-c1ccnc(C(F)(F)F)c1- Mol. weight
- 490.46 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4167360 ↗
Also known as
- idh305
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02977689 | Phase 2 | Jul 1, 2017 | New York University, Novartis |
| NCT02987010 | Phase 2 | Jan 1, 2017 | The University of Texas, Dallas |
| NCT02826642 | Phase 1 | Aug 1, 2016 | Novartis |
| NCT02381886 | Phase 1 | Mar 1, 2015 | Novartis |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 3 | 2 | 2 | 2015 |
| New York University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 1 | 1 | 2017 |
3 organizations
Page 1 / 1